"We're not doing 30 bets a year": Vijay Pande on betting small after running $4 billion at a16z
Vijay Pande, who departed from a16z's $4 billion biotech fund to launch the smaller, AI-focused VZVC, discusses his shift toward a more selective investment strategy. He highlights biology's transformation from a discovery-driven science to an engineering discipline, while identifying clinical trial costs as a persistent bottleneck and emphasizing that open, collaborative datasets—rather than proprietary ones—are essential for AI to truly revolutionize medicine.
1 Article
Trace's outlet lean is shown first — tap Left / Center / Right on each source to add your rating too.
- TechCrunchTrace: Center
“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z
Vijay Pande, who departed from a16z's $4 billion biotech fund to launch the smaller, AI-focused VZVC, discusses his shift toward a more selective investment strategy. He highlights biology's transformation from a discovery-driven science to an engineering discipline, while identifying clinical trial costs as a persistent bottleneck and emphasizing that open, collaborative datasets—rather than proprietary ones—are essential for AI to truly revolutionize medicine.
Rate outletRead original